DIA: Driving Insights to Action
Science:Life Sciences
With more than 30 leading multinational pharmaceutical companies choosing Singapore as their base for operations in this region, this island nation has emerged as one of the most advanced biomedical R&D hubs in Asia. “The Singapore government understands the importance for Singapore, as a small country, to follow international standards,” explains Jin Shun, Head of Regulatory Affairs, Asia-Pacific, Middle East and Africa, for Sandoz, a Unit of Novartis. “HSA (the Health Sciences Authority) joined ICH in November 2017, and announced the implementation of eCTD at the end of last year.” Mr. Shun serves on the program committee for the DIA-CoRE Singapore Annual Meeting 2019.
Master Protocol Efficiencies Speeding COVID-19 Treatments
Found in Translation: A Tumultuous Year in Review
Biosimilar Awareness, Access and Savings Continue to Grow
R2D2 Aligning Regulatory and HTA Review to Quicken Patient Access
Jump In, Be Brave, Have the Conversation – Reducing Health Disparities among Minority Patients
CTD Speeding Medicines Registration in East Africa
Biosimilar Savings and Their Price: BPCIA Turns Ten
Regulators Promote Reliance as 21st Century Best Practice
Regulatory and Clinical Science Align to Fight COVID-19
DIA Keynote Calls for Expanded COVID-19 Trial Parameters
Impact Philanthropy Accelerating Cures Within Reach
FDA Guidance: Flexibility But No Compromise on Patient Safety
Digital Tools Powering More and Safer Clinical Trials
Latin America's COVID-19 Regulatory Response
Partnerships Essential to SAHPRA Pandemic Response
EFPIA Shares Industry View of EMA Regulatory Framework
Time to Press the Pause Button on Speedy Drug Approvals?
Reach More Patients While Improving Data Quality?
ATMPs May Deliver on Promise of Individualized Medicine
Relevance Will Put Europe on Investment Fast Track
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Terrace | تراس